Clinical Trial Update: A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC [Phase 1, Phase 2]

View source ↗

Summary

This document describes a Phase 1/2 clinical trial evaluating the safety, tolerability, and pharmacokinetics of JIN-A02 in patients with EGFR-mutant advanced no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• JIN-A02

Snippet

Sponsor: J Ints Bio | Conditions: EGFR Mutant Advanced Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: RECRUITING